Compare EEIQ & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEIQ | LYRA |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.6M |
| IPO Year | 2021 | 2020 |
| Metric | EEIQ | LYRA |
|---|---|---|
| Price | $0.26 | $2.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 224.0K | 126.1K |
| Earning Date | 01-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,358,301.00 | $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 44.99 | N/A |
| 52 Week Low | $0.20 | $1.63 |
| 52 Week High | $1.74 | $37.50 |
| Indicator | EEIQ | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 31.94 |
| Support Level | $0.28 | $1.63 |
| Resistance Level | $0.29 | $2.58 |
| Average True Range (ATR) | 0.03 | 0.29 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 15.92 | 16.45 |
EpicQuest Education Group International Ltd provides comprehensive education solutions for domestic and international students interested in university and college degree programs in the U.S., Canada, and the UK. In addition, the company has a recruiting relationship with the regional campuses of Miami University of Ohio, where it maintains residential facilities, a full-service cafeteria, recreational facilities, shuttle buses, and an office for the regional campuses that provides study abroad and post-study services for its students; these facilities are not owned, maintained, operated or are part of Miami University. Company operated in three primary reportable segments foreign language education (QHI), foreign language education (RIL) and the professional training programs.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.